Literature DB >> 22698783

Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.

Deyong Ye1, Qian Shi, Chung-Hang Leung, Seung-Whan Kim, Shin-Young Park, Elizabeth A Gullen, Zao Li Jiang, Hao Zhu, Susan L Morris-Natschke, Yung-Chi Cheng, Kuo-Hsiung Lee.   

Abstract

Two conjugates (1 and 2) of camptothecin (CPT) and 4β-anilino-4'-O-demethylepipodophyllotoxin were previously shown to exert antitumor activity through inhibition of topoisomerase I (topo I). In this current study, two novel conjugates (1E and 2E) with an open E-ring in the CPT moiety were first synthesized and evaluated for biological activity in comparison with their intact E-ring congeners. This novel class of CPT-derivatives exhibits its antitumor effect against CPT-sensitive and -resistant cells, in part, by inhibiting topo I-linked DNA (TLD) religation. An intact E-ring was not essential for the inhibition of TLD religation, although conjugates with an open E-ring were less potent than the closed ring analogs. This lower religation potency resulted in decreased formation of protein-linked DNA breaks (PLDBs), and hence, less cell growth inhibition. In addition to their impact on topo I, conjugates 1E, 2, and 2E exhibited a minor inhibitory effect on topo II-induced DNA cleavage. The novel structures of 1E and 2E may present scaffolds for further development of dual function topo I and II inhibitors with improved pharmacological profiles and physicochemical properties.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698783      PMCID: PMC3389137          DOI: 10.1016/j.bmc.2012.05.030

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  32 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.

Authors:  D Perrin; B van Hille; J M Barret; A Kruczynski; C Etiévant; T Imbert; B T Hill
Journal:  Biochem Pharmacol       Date:  2000-04-01       Impact factor: 5.858

Review 3.  Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.

Authors:  S Salerno; F Da Settimo; S Taliani; F Simorini; C La Motta; G Fornaciari; A M Marini
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

4.  X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance.

Authors:  Shin-Young Park; Wing Lam; Yung-chi Cheng
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

5.  Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.

Authors:  J Y Chang; X Guo; H X Chen; Z Jiang; Q Fu; H K Wang; K F Bastow; X K Zhu; J Guan; K H Lee; Y C Cheng
Journal:  Biochem Pharmacol       Date:  2000-03-01       Impact factor: 5.858

Review 6.  Review camptothecin: current perspectives.

Authors:  Qing-Yong Li; Yuan-Gang Zu; Rong-Zhen Shi; Li-Ping Yao
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 7.  Dual topoisomerase I/II inhibitors in cancer therapy.

Authors:  William A Denny; Bruce C Baguley
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

8.  Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.

Authors:  Amélie Lansiaux; Stéphane Léonce; Laurence Kraus-Berthier; Christine Bal-Mahieu; Romain Mazinghien; Sébastien Didier; Marie-Hélène David-Cordonnier; Patrick Hautefaye; Gilbert Lavielle; Christian Bailly; John A Hickman; Alain Pierré
Journal:  Mol Pharmacol       Date:  2007-05-09       Impact factor: 4.436

9.  Substituent effects on the thermodynamic stability of imines formed from glycine and aromatic aldehydes: implications for the catalytic activity of pyridoxal-5'-phosphate.

Authors:  Juan Crugeiras; Ana Rios; Enrique Riveiros; John P Richard
Journal:  J Am Chem Soc       Date:  2009-11-04       Impact factor: 15.419

10.  Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.

Authors:  V Pavillard; D Kherfellah; S Richard; J Robert; D Montaudon
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

View more
  4 in total

1.  Toward synthesis of third-generation spin-labeled podophyllotoxin derivatives using isocyanide multicomponent reactions.

Authors:  Liang Kou; Mei-Juan Wang; Li-Ting Wang; Xiao-Bo Zhao; Xiang Nan; Liu Yang; Ying-Qian Liu; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Eur J Med Chem       Date:  2014-01-29       Impact factor: 6.514

2.  Design and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents.

Authors:  Xiao-Bo Zhao; Masuo Goto; Zi-Long Song; Susan L Morris-Natschke; Yu Zhao; Dan Wu; Liu Yang; Shu-Gang Li; Ying-Qian Liu; Gao-Xiang Zhu; Xiao-Bing Wu; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem Lett       Date:  2014-06-27       Impact factor: 2.823

3.  A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells.

Authors:  Ke-Jia Wu; Jie-Min Huang; Hai-Jing Zhong; Zhen-Zhen Dong; Kasipandi Vellaisamy; Jin-Jian Lu; Xiu-Ping Chen; Pauline Chiu; Daniel W J Kwong; Quan-Bin Han; Dik-Lung Ma; Chung-Hang Leung
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

4.  A Novel Cytotoxic Conjugate Derived from the Natural Product Podophyllotoxin as a Direct-Target Protein Dual Inhibitor.

Authors:  Ángela-Patricia Hernández; Paula Díez; Pablo A García; Martín Pérez-Andrés; Pablo Ortega; Pablo G Jambrina; David Díez; María Ángeles Castro; Manuel Fuentes
Journal:  Molecules       Date:  2020-09-17       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.